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Background/aim: We aimed to discuss term infants who are given surfactant due to respiratory disorder according to the underlying
etiology, the dose of surfactant administration, and the need for repeated surfactant administration.
Materials and methods: In this retrospective study infants hospitalized in the 4th level neonatal intensive care unit during January
2019 and December 2021 and administered surfactant due to respiratory distress were included. Term infants given surfactant due
to respiratory failure were included in the study through the data recording system. The number of surfactant doses, indications for
administration, mortality, duration of hospitalization, intubation time, and inotrope use were recorded in the infants included in the
study.
Results: During the two-year period, 1250 infants were hospitalized in our neonatal intensive care unit. Of those, 56 infants received
surfactant replacement therapy for severe respiratory failure. There were 30 infants with pneumonia, 4 infants with meconium aspiration
syndrome (MAS), and 22 infants with transient tachypnea of the newborn (TTN). It was seen that single-dose administration was higher
in patients with TTN (p = 0.01), while multiple-dose surfactant administration was more common in patients with MAS, resulting in
a statistical difference (p = 0.02). Mortality was lower, especially in cases given early surfactant administration and this situation was
statistically significant (p < 0.001). Duration of intubation was 5.05 ± 4.7 days in early surfactant administration group and 8.0 ± 6.1
days in late surfactant administration group. This difference was statistically significant (p = 0.04). While early surfactant application was
statistically higher in the TTN group (p = 0.007), late surfactant application was statistically higher in the pneumonia group (p = 0.001).
Conclusion: Despite the difference on administration time and repeat dose interval due to etiology, surfactant treatment is improving
the respiratory distress of term infants.
Key words: Morbidity, mortality, respiratory failure, surfactant, term infant

1. Introduction
Respiratory distress syndrome (RDS) is the most
common respiratory failure condition in preterm
infants. This situation increases as the gestational week
of the infant decreases. However, respiratory distress
is a very important problem not only for preterm
infants but also for term infants [1]. Although there
are many risk factors for the etiology of respiratory
distress in newborn infants, cesarean delivery, which
has increased in recent years, poses a very important
risk [2]. There is an inversely proportional relationship
between respiratory distress and gestational age in
term newborn infants and the incidence of respiratory
distress decreases as the gestational week progresses [2].

There are many reasons that cause respiratory distress
in the neonatal period, the most common reason
of respiratory distress is due to pulmonary causes.
When the pulmonary causes of respiratory distress in
term infants are examined, causes such as transient
tachypnea of the newborn (TTN), neonatal pneumonia,
pneumothorax, and pulmonary hypertension are the
leading causes [3]. In these cases, the surfactant may
be needed, similar to respiratory distress syndrome in
preterm infants. In this study, we aimed to discuss term
infants who are given surfactant due to respiratory
disorder according to the underlying etiology, the dose
of surfactant administration and the need for repeated
surfactant administration.
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2. Materials and methods
This is a retrospective and descriptive study, and the study
was conducted by Health Sciences University İzmir Dr.
Behçet Uz Pediatrics and Surgery Training and Research
Hospital. Infants hospitalized in the 4th level neonatal
intensive care unit and administered surfactant due to
respiratory distress were included. Our unit is the largest
neonatal intensive care unit in the Aegean region and
includes 58 beds. It serves around 1500 newborn infants
annually.
Term infants hospitalized due to respiratory distress for
a period of two years (2019 January to 2021 December) were
included in the study. In newborns, tachypnea (respiratory
rate > 60/min) and tachycardia (peak heart rate > 160/
min), cyanosis, nasal flaring, apnea/dyspnea, groaning,
and chest wall retractions are defined as respiratory failure
[4]. In accordance with this definition, term infants given
surfactant due to respiratory failure were included in the
study through the data recording system. The number of
surfactant doses, indications for administration, mortality,
duration of hospitalization, intubation time, and inotrope
use were recorded in the infants included in the study.
Cases with major structural congenital anomaly, cardiac
problem, diagnosed with metabolic disease in the followup and genetic malformation were not included.
Diagnostic criteria for the lung diseases were as
follows: [1] Transient tachypnea of the newborn:
Transient tachypnea of the newborn is a diagnosis based
on clinical and radiological findings. Often, the diagnosis
of TTN is made by excluding other diagnoses such as
RDS, pneumonia, and pneumothorax [5]. If the signs of
respiratory distress increase, the fractionated inhaled
02 (FiO2) requirement exceeds 40%, there are abnormal
chest X-ray findings, or if the baby does not improve even
after two h, infant should be hospitalized in the neonatal
intensive care unit [2,6]. Meconium aspiration syndrome
(MAS): It is a picture that progresses with varying degrees
of respiratory distress and hypoxic respiratory failure due
to inhalation of meconium and amniotic fluid during fetal
life or birth. Meconium aspiration syndrome is defined as
the presence of respiratory distress in the first two h of life,
the need for oxygen support, and the absence of any other
explainable airway, lung, or congenital heart malformation
[7]. Respiratory distress in an infant born through
meconium-stained amniotic fluid whose respiratory and
radiological signs cannot be otherwise explained [2].
Pneumonia: Pneumonia is the inflammatory process of
the lung. It is diagnosed with clinical, radiological and
microbiological findings. Because pneumonia findings
are nonspecific, patients with sudden onset respiratory
distress should be evaluated for pneumonia with complete
blood count, acute phase reactants, culture and chest
X-ray, including complete sepsis evaluation [8].
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Pulmonary hypertension was defined as elevated
right ventricular and pulmonary artery pressure leading
to right to-left ductal or foramen shunt detected by
echocardiography, a routine procedure in our NICU for
the patients suffering from severe respiratory failure.
Surfactant was prepared according to the methods
described in a published trial and administrated at a
dose of 100 mg/kg [9]. Poractant alfa (Chiesi, Italy) was
used for all patients. Surfactants were administered if
the infants had fractionated inhaled oxygen levels higher
than 60% or persistent low saturation levels (<85%).
Surfactant administration in the first 4 h was accepted
as early, surfactant application after 24 h was considered
as late surfactant treatment. Two or more surfactant
administrations were considered as multiple dose
surfactant application. The primary outcome was mortality
and secondary outcome was duration of the oxygen
support according to early surfactant administration.
The research protocol was fully approved by local ethics
committee.
Statistical data were analyzed by using the Statistical
package for the Social Sciences (SPSS) 15.0 software (SPSS
Inc., Chicago, IL). Continuous variables were compared by
using Mann-Whitney U-test. Categorical variables were
analyzed by chi-square test or Fisher’s exact test. A p-value
of <0.05 was accepted as statistically significant.
3. Results
During the two-year period, 1250 infants were hospitalized
in our neonatal intensive care unit (NICU). Of those, 56
term infants received surfactant replacement therapy for
severe respiratory failure. Demographic characteristics
of the patients are given in Table 1. There were 30 infants
with pneumonia, 4 infants with MAS and 22 infants
with TTN. Pulmonary air leak syndrome was not seen
whereas pulmonary hemorrhage occurred in one infant
with MAS. Two infants with TTN died and 6 infants
died due to pneumonia. One infant with MAS died.
We did not administer surfactant to any patients due to
ARDS, pulmonary hemorrhage. Infants with congenital
diaphragmatic hernia and major congenital anomalies
were excluded from the trial. Pulmonary hypertension
was developed in 10 infants but they did not require inhale
nitric oxid treatment. Nine infants died with a mortality
rate of 16%. Mortality rate was higher in patients with
MAS.
A single dose of surfactant was administered to 73.2%
of the infants included in the study. When infants were
evaluated according to single and multiple dose surfactant
administration, it was seen that single dose administration
was higher in infants with TTN (p = 0.01), while multipledose surfactant administration was more common in
infants with MAS, resulting in a statistical difference (p =
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0.02). The rate of inotropic agent use was 66.6% in the group
given multiple doses and it was statistically significant (p =
0.006). The duration of mechanical ventilation was found
to be longer in infants given multiple doses of surfactant (p
= 0.001). It is shown in detail in Table 2.
In the evaluation of mortality and surviving infants,
mortality was higher in infants using inotropes (p = 0.04).
It was determined that two infants died due to TTN
and these two infants received late surfactant treatment.
It was observed that 15 of the infants diagnosed with

pneumonia received late surfactant treatment, and all of
the infants hospitalized due to MAS were treated with
early surfactant.
When the surfactant was evaluated according to the
time of administration, it was seen that mortality was
lower especially in cases given early and this situation was
statistically significant (p < 0.001). Similarly, the duration
of stay in the mechanical ventilator was found to be
shorter in infants treated with early surfactant (p = 0.04).
It is shown in detail in Table 3.

Table 1. Demographic characteristics of the infants included in the trial.
Gestational week (wk)*

38.0 ± 1.14

Birth weight (g)*

2966 ± 500

Male sex (%)

30 (53.5)

Cesarean section (%)

48 (85.7)

Primiparous pregnant women (%)

10 (17.8)

Single dose surfactant (%)

41 (73.2)

Multiple doses surfactant (%)

15 (26.7)

Mortality (%)

9 (16)

Early surfactant administration (%)

39 (69.6)

Number of surfactant doses *

1.4 ± 0.75

Postnatal age of surfactant treatment (hour)*

10 ± 12

*As presented mean ± SD.

Table 2. Evaluation of infants according to the number of surfactant doses.
Single dose (n = 41)

Multiple doses (n = 15)

p

Gestational week (wk)*

37.9 ± 1.0

38.2 ± 1.3

0.29

Birth weight (g)*

2928 ± 491

3070.6 ± 528

0.35

Male sex (%)

22 (53)

8 (53)

1.00

Cesarean section frequency (%)

36 (87)

12 (80)

0.66

TTN (%)

20 (48)

2 (13)

0.01

Pneumonia (%)

20 (48)

10 (66)

0.23

MAS (%)

1 (2)

3 (20)

0.02

Use of inotropes (%)

11 (26.8)

10 (66.6)

0.006

Mortality (%)

5 (12)

4 (26.6)

0.22

Duration of hospitalization (day)*

19.6 ± 13.9

23.8 ± 15.8

0.28

Duration of intubation (day)*

5.17 ± 5.5

8.0 ± 3.9

0.001

*As presented mean ± SD.
TTN: Transient tachypnea of the newborn
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Table 3. Evaluation of surfactant by time of administration.
Early administration (n = 39)

Late administration (n = 17)

p

Mortality (%)

0 (0)

4 (23.5)

<0.001

Duration of hospitalization (day)*

19.0 ± 12.6

24.7 ± 17.7

0.30

Duration of intubation (day)*

5.05 ± 4.7

8.0 ±6.1

0.04

Use of inotropes (%)

15 (38)

6 (35)

1.0

MAS (%)

4 (10)

0 (0)

0.17

Pneumonia (%)

15 (38)

15 (88)

0.001

TTN (%)

20 (51)

2 (11)

0.007

*As presented mean ± SD.

4. Discussion
In this trial we aimed to investigate the surfactant usage
in term respiratory disorders. We found that surfactant
treatment is an important point for the term respiratory
failure. Fifty-six infants received surfactant replacement
therapy for severe respiratory failure and pneumonia is
the most common surfactant treatment indication at the
NICU admission. We also found that single dose surfactant
administration was higher in TTN, and mortality was
lower especially in cases given early surfactant application.
Respiratory distress syndrome is a major cause of
morbidity and mortality in preterm neonates [1,10].
Pulmonary surfactant deficiency is the primary cause of
respiratory distress syndrome. It affects 40%–50% of the
neonates born before 32 weeks of gestation and results in
high morbidity and mortality [11]. Surfactant-replacement
therapy is a life-saving treatment for preterm infants
with the introduction of surfactant treatment, especially
premature mortality has decreased significantly [12].
Transient tachypnea of newborn is one of the most
common causes of neonatal respiratory distress. Increased
fluid volume in the airways, uterine contractions,
pulmonary immaturity, and genetic predisposition are
involved in the pathophysiology of TTN. Vaginal or
cesarean delivery without medical indication should be
avoided before the 39th gestational week [13]. Although
the gestational age of all infants included in our study is
38 weeks and above, the high cesarean section ratio creates
a very important risk for TTN. Another important point
is that the patients we followed up for TTN needed a
single dose of surfactant treatment. Only 2 term infants
with TTN needed multiple dose of surfactant treatment.
This led to a statistical difference. It has been suggested
that there may be problems related to the production and
function of surfactant, especially in the first hours of life.
In a study conducted with this hypothesis, 42 infants with
TTN were evaluated and they found that low lamellar
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body counts are associated with decreased surfactant
function, suggesting that prolonged disease is associated
with surfactant abnormalities [14]. A similar study was
done by Fiori et al. [15] and deficiency or dysfunction of
the surfactant system is involved in the majority of cases
of respiratory distress in near term and possibly term
infants. In another study which 544 infants were born
to via elective cesarean delivery examined and oral fluid
samples were obtained in the delivery room immediately
after birth, and gastric fluid was collected within the first
hour of life [16]. They suggest that TTN was associated
with surfactant dysfunction. In parallel with these studies,
we found the frequency of surfactant application was high
in TTN and compared whether early/late single/multiple
dose application had an effect, unlike other studies. In
line with the data of our study, early administration
of surfactant may be considered in cases of increased
respiratory distress in patients hospitalized in the NICU
due to TTN during follow-up.
Meconium aspiration syndrome is caused by
inflammation in the airways and can cause severe
obstructive pulmonary disease with significant increase
in airway resistance, airway obstruction leading to
emphysema, and/or atelectasis (if the involved airway
is completely obstructed) [17]. The disease is usually
pulmonary involvement due to widespread atelectasis and
over-ventilated areas, indicating a high risk of air leaks [17].
Also, meconium inactivates surfactant and thus can cause
an acute respiratory distress syndrome such as restrictive
lung disease, which can be managed at higher rates or with
high frequency ventilation and/or surfactant replacement
therapy [18]. Typically, meconium aspiration often results
in increased lung resistance. The combination of impaired
airway mechanics combined with surfactant dysfunction
creates a nonhomogeneous lung disease, complicating the
management of severe MAS [19]. In the Cochrane metaanalysis, it was stated that the administration of surfactant
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in infants with MAS had no effect on mortality, but the
studies were not homogeneous [20]. It was stated that
the application of surfactant in these infants reduced the
severity of respiratory disease and reduced the course to
extracorporeal membrane oxygenation [20]. Although
surfactant dysfunction is often present at the start of
invasive respiratory support, conventional mechanical
ventilation may further compromise its function. Therefore,
it is vital to apply it in the early stages of the disease. In our
study, we found that multiple-dose surfactant applications
were high in infants with MAS. Although the number of
cases is small, multiple-dose surfactant treatment may be
necessary in MAS, and this is often life-saving.
Pneumonia is the inflammatory process of the lung.
It has an important place in neonatal infections and is an
important cause of morbidity and mortality in developing
countries. In pneumonia, there is usually increased
permeability of both the endothelial and epithelial barriers,
increasing the influx of plasma proteins into the alveolar
space [21]. At the same time, pulmonary surfactant is
an important part of the host defense against respiratory
infections. Substances secreted directly by bacteria impair
surfactant synthesis directly and indirectly through
pulmonary type 2 epithelial cells. The interaction of bacteria
or endotoxin with the secreted surfactant causes changes in
the physical (i.e. density and surface tension) properties of
the surfactant. Changes in surfactant have a detrimental
effect on lung function, characterized by significant
decreases in total lung capacity, static compliance, diffusion
capacity and arterial partial oxygen pressure, and a
significant increase in mean pulmonary artery pressure. In
addition, reduced surfactant concentrations or an altered
surfactant composition can cause anatomical changes
commonly seen in pneumonia, such as pulmonary edema,
hemorrhage, and atelectasis [22].
A 2012 Cochrane meta-analysis found no evidence
from randomized controlled trials to support or disprove
the efficacy of surfactant in late preterm and term infants

with proven or suspected bacterial pneumonia, but it
has been clearly demonstrated that surfactant is affected
in the case of pneumonia [23]. In our study, the need for
surfactant was mostly required in infants hospitalized for
pneumonia. Both single and multiple doses of surfactant
were needed in these infants. However, surfactant use is
higher in the late period because these infants usually have
late-onset pneumonia. There are small studies showing
that surfactant treatment may be needed and even multiple
dose applications may reduce mortality in patients who
are hospitalized in the NICU with a pneumonia clinic and
whose general condition deteriorates [24,25]. Therefore,
we think that the administration of surfactant in newborns
with pneumonia is very important, especially in cases
with a poor clinical course. In this study, surfactant
administration time was mostly after 24 h in infants who
were administered surfactant for pneumonia, which we
attribute to the rapid deterioration of these patients. Close
follow-up of infants who are at risk for pneumonia is very
essential for term infants with a respiratory disorder.
The small number of patients in our study is the most
important limitation. In studies involving large patient
populations, we can get more ideas about surfactant
administration, time of administration and dose frequency,
especially in term infants presenting with respiratory
distress.
In conclusion, this study is the first to investigate
whether there is a difference in the etiology, dose frequency,
and time of surfactant administration in term infants
hospitalized in the NICU due to respiratory distress and
treated with surfactant.
Acknowledgment/disclaimers/conflict of interest
All authors declare no conflict of interest.
Informed consent
This study was approved by the ethics committee of Behcet
Uz Children’s Hospital (approval code: 2022/760).

References
1.

Ozkan H, Erdeve O, Kutman HGK. Turkish Neonatal Society
guideline on the management of respiratory distress syndrome
and surfactant treatment. Turkish Archives of Pediatrics 2018;
53 (1): 45-54. https://doi:10.5152/TurkPediatriArs.2018.0180

2.

3.

4.

Kim JH, Lee SM, Lee YH. Risk factors for respiratory distress
syndrome in full-term neonates. Yeungnam University Journal
of Medicine 2018; 35 (2): 187-191. https.//doi:10.12701/
yujm.2018.35.2.187

Baseer KAA, Mohamed M, Abd-Elmawgood EA. Risk
factors of respiratory diseases among neonates in neonatal
intensive care unit of Qena University Hospital, Egypt.
Annals of Global Health 2020; 86 (1): 22. https://doi:10.5334/
aogh.2739

5.

Condo V, Cipriani S, Colnaghi M, Bellu R, Zahnini R et al.
Neonatal respiratory distress syndrome: are risk factors the
same in preterm and term infants? Journal of Maternal-Fetal
&Neonatal Medicine 2017; 30 (11): 1267-1272.

Engle WA, American Academy of Pediatrics Committee on
F, Newborn. Surfactant replacement therapy for respiratory
distress in the preterm and term neonate. Pediatrics 2008; 121
(2): 419-432. https://doi:10.1542/peds.2007-3283

6.

Eunice Hagen AC, Cheryl Lew. Transient tachypnea of the
newborn. NeoReviews 2017; 18: 141-148.

1783

ALKAN ÖZDEMİR et al. / Turk J Med Sci
7.

Haakonsen Lindenskov PH, Castellheim
Mollnes TE. Meconium aspiration
pathophysiological mechanisms and
therapies. Neonatology 2015; 107 (3):
doi:10.1159/000369373

A, Saugstad OD,
syndrome:possible
future potential
225-230. https://

17. Oliveira CPL, Flor-de-Lima F, Rocha GMD, Machado AP,
Guimaraes Pereira Areias MHF. Meconium aspiration
syndrome: risk factors and predictors of severity.
J
Matern Fetal Neonatal Med. 2019; 32(9): 1492. https://doi:
10.1080/14767058.2017.1410700

8.

Nissen MD. Congenital and neonatal pneumonia. Paediatric
Respiratory Reviews 2007; 8 (3): 195-203. https://doi:10.1016/j.
prrv.2007.07.001

9.

Enhorning G, Shennan A, Possmayer F, Dunn M, Chen CP
et al. Prevention of neonatal respiratory distress syndrome by
tracheal instillation of surfactant: a randomized clinical trial.
Pediatrics 1985; 76 (2): 145-153. https://pubmed.ncbi.nlm.nih.
gov/3895150

18. Middleton P, Shepherd E, Crowther CA. Induction of labour
for improving birth outcomes for women at beyond or term.
Cochrane Database Systematic Reviews 2018; 5: CD004945.
https://doi:10.1002/14651858.CD004945.pub4
19. Hahn S, ChoiHJ, Soll R, Dargaville PA. Lung lavage for
meconium aspiration syndrome in newborn infants. Cochrane
Database of Systematic Reviews 2013; 4: CD003486. https://
doi:10.1002/14651858.CD003486.pub2

10. Permall DL, Pasha AB,Chen XQ. Current insights in noninvasive ventilation for the treatment of neonatal respiratory
disease. Italian Journal of Pediatrics 2019; 45 (1): 105. https://
doi:10.1186/s13052-019-0707-x

20. El Shahed AI, Dargaville PA, Ohlsson A, Soll R. Surfactant
for meconium aspiration syndrome in term and late preterm
infants. Cochrane Database Systematic Reviews 2014; (12):
CD002054. https://doi:10.1002/14651858.CD002054.pub3

11. McPherson C, Wambach JA. Prevention and treatment
of respiratory distress syndrome in preterm neonates.
Neonatal Network 2018; 37 (3): 169-177. https://
doi:101891/07300832.37.3.169

21. Polin RA, Carlo WA. Surfactant replacement therapy for
preterm and term neonates with respiratory distress. Pediatrics
2014; 133: 156-163. https://doi:10.1542/peds.2013-3443

12. Sweet DG, Carnielli V, Greisen G, Hallman M, Ozek E et
al. European Consensus Guideline on the Management of
Respiratory Distress Syndrome-2019 Update. Neonatology
2019; 115 (4): 432-450. https://doi:10.1159/000499361
13. Guglani L, Lakshminrusimha S, Ryan RM. Transient tachypnea
of the newborn. Pediatrics in Review 2008; 29 (11): 59-65.
https://doi:10.1542/pir.20-11-e59
14. Machado LU, Fiori HH, Baldisserotto M, Ramos Garcia PC,
Vieira AC et al. Surfactant deficiency in transient tachypnea of
the newborn. The Journal of Pediatrics 2011; 159 (5): 750-754.
https://doi:10.1016/j.jpeds.2011.04.023
15. Fiori HH, Henn R, Baldisserotto M, Bica IG, Fiori RM.
Evaluation of surfactant function at birth determined by the
stable microbubble test in term and near term infants with
respiratory distress. European Journal of Pediatrics 2004; 163
(8): 443-448. https://doi:10.1007/s00431-004-1473-2
16. Estorgato GR, Fiori HH, da Silva Ribeiro MA, de Paula D,
Garcia PC et al. Surfactant deficiency in full-term newborns
with transient tachypnea delivered by elective C-section.
Pediatric Pulmonology 2016; 51 (6): 596-600. https://
doi:10.1002/ppul.23338

1784

22. Brogden KA. Changes in pulmonary surfactant during bacterial
pneumonia. Antonie Van Leeuwenhoek 1991; 59 (4): 215-223.
https://doi:10.1007/BF00583673
23. Tan K, Lai NM, Sharma A. Surfactant for bacterial pneumonia
in late preterm and term infants. Cochrane Database Systematic
Reviews 2012; CD008155. https://doi:10.1002/14651858.
CD008155.pub2
24. Alkan S, Ozer EA, Ilhan O, Sutcuoglu S, Tatli M. Surfactant
treatment for neonatal respiratory disordes other than
respiratory distress syndrome. The Journal of Maternal-Fetal &
Neonatal Medicine 2015; 28 (2): 131-133. https://doi:10.3109/1
4767058.2014.906575
25. Gortner L, Pohlandt F, Bartmann P. Effect of bovine surfactant
in very low birth weight premature infants with congenital
pneumonia. Monatsschr Kinderheilkd 1990; 16: 101-108.
https://pubmed.ncbi.nlm.nih.gov/2377170

